ProCE Banner Activity

Maximizing Safety and Efficacy of ADCs in Patients With HER2-Low or Ultralow mBC

Slideset

Download these slides from an ASCO 2025 live satellite symposium on HER2-low and HER2-ultralow mBC covering the key safety profile of antibody–drug conjugates, including guidelines and expert recommendations on how to manage adverse events with these agents.

Released: May 20, 2025

Expiration: November 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.